Medical Marijuana, Inc. Subsidiary HempMeds® Brasil


SAN DIEGO, CA, Feb. 24 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the first-ever products, brands and supply chain of cannabis-derived nutraceuticals, today announced that its subsidiary HempMeds® Brasil is sponsoring the first Obesity Medicine Symposium of the Brazilian Society of Obesity Medicine from March 3-6, 2022.

The symposium, which will take place at the Centro South Convention Center in Santa Catarina, is designed to bring together educators, wellness organizations and medical professionals to discuss new techniques and technological advances in obesity medicine. HempMeds® Brasil chose to sponsor and present this event to educate people on how cannabidiol (CBD) plays a vital role in our daily wellness routines.

“This is a great opportunity for us to educate people about what CBD is, its potential wellness benefits, and ongoing research into how CBD can be used by people around the world. “, said Matheus Patelli, General Manager of HempMeds® Brasil. . “CBD can be legally imported into Brazil and is subsidized by the Brazilian government for many indications so people understand how and why they should take it.”

In addition to sponsoring the event, HempMeds® Brasil will host a presentation at the March 4 Symposium on Medical Cannabis and CBD, including the variety of products that exist in Brazil, wellness applications, and information on the legality and safety.

“We have experienced exceptional operational and revenue growth in Brazil over the past few years and our invitation to sponsor this event is a testament to our strong brand presence there,” said Medical Marijuana, Inc. CEO Blake Schröder. “In partnership with some of Brazil’s most prestigious doctors and researchers, we have created lasting relationships with Brazilian consumers based on transparency, education and trust.”

To learn more about HempMeds® Brasil, please visit

About HempMeds® Brazil

HempMeds® Brasil was the first company to receive approval from the National Health Surveillance Agency (Anvisa) to import a product based on cannabidiol, a substance derived from hemp, a plant of the genus Cannabis. Currently, it is authorized to supply its products, which help control diseases such as epilepsy, Parkinson’s disease, chronic pain and multiple sclerosis, under medical prescription. For these indications, products may be subsidized by the Brazilian government. HempMeds® Brasil is working on additional approvals for other indications.

About Medical Marijuana, Inc.

We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct non-psychoactive cannabinoid business units: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in providing the highest quality non-psychoactive legal cannabis products derived from industrial hemp; and a clinical research and development sector for cannabinoid-based botanical drugs led by its pharmaceutical investment companies and partners, including AXIM® Biotechnologies, Inc. and Neuropathix. Medical Marijuana, Inc. has been named one of CNBC’s Top CBD Producers. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina and Paraguay and is a leader in developing international markets. The company’s flagship product, Real Scientific Hemp Oil, has been used in several successful clinical studies in Mexico and Brazil to understand its safety and efficacy.

Medical Marijuana, Inc. is headquartered in San Diego, CA, and additional information is available at or by visiting To view the Medical Marijuana, Inc. corporate video, click here.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by these articles. This document contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. These forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to differ materially from the statements made herein.


These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.


Medical Marijuana, Inc. does not sell or distribute any product that violates the United States Controlled Substances Act.


Public relations contact:
Katherine Brown
Account director
CMW Media
[email protected]

Contact with Investor Relations:
T. (858) 283-4016
[email protected]

Source link


Comments are closed.